A
Alvin F. Wong
Researcher at Onyx Pharmaceuticals
Publications - 22
Citations - 1750
Alvin F. Wong is an academic researcher from Onyx Pharmaceuticals. The author has contributed to research in topics: Carfilzomib & Bortezomib. The author has an hindex of 12, co-authored 22 publications receiving 1654 citations.
Papers
More filters
Journal ArticleDOI
A phase 2 study of single-agent carfilzomib (PX-171-003-A1) in patients with relapsed and refractory multiple myeloma
David S. Siegel,Thomas Martin,Michael Wang,Ravi Vij,Andrzej Jakubowiak,Sagar Lonial,Suzanne Trudel,Vishal Kukreti,Nizar J. Bahlis,Melissa Alsina,Asher Chanan-Khan,Francis K. Buadi,Frederic J. Reu,George Somlo,Jeffrey A. Zonder,Kevin W. Song,A. Keith Stewart,Edward A. Stadtmauer,Lori Kunkel,Sandra Wear,Alvin F. Wong,Robert Z. Orlowski,Sundar Jagannath +22 more
TL;DR: Durable responses and an acceptable tolerability profile in this heavily pretreated population demonstrate the potential of carfilzomib to offer meaningful clinical benefit.
Journal ArticleDOI
An open-label, single-arm, phase 2 (PX-171-004) study of single-agent carfilzomib in bortezomib-naive patients with relapsed and/or refractory multiple myeloma
Ravi Vij,Michael Wang,Jonathan L. Kaufman,Sagar Lonial,Andrzej Jakubowiak,A. Keith Stewart,Vishal Kukreti,Sundar Jagannath,Kevin T. McDonagh,Melissa Alsina,Nizar J. Bahlis,Frederic J. Reu,Nashat Gabrail,Andrew R. Belch,Jeffrey Matous,Peter P. Lee,Peter Rosen,Michael Sebag,David H. Vesole,Lori Kunkel,Sandra Wear,Alvin F. Wong,Robert Z. Orlowski,David S. Siegel +23 more
TL;DR: The results of the present study support the use of carfilzomib in R/R MM patients with relapsed and/or refractory multiple myeloma.
Journal ArticleDOI
An open-label, single-arm, phase 2 study of single-agent carfilzomib in patients with relapsed and/or refractory multiple myeloma who have been previously treated with bortezomib
Ravi Vij,David S. Siegel,Sundar Jagannath,Andrzej Jakubowiak,Alexander Keith Stewart,Kevin T. McDonagh,Nizar J. Bahlis,Andrew Belch,Lori Kunkel,Sandra Wear,Alvin F. Wong,Robert Z. Orlowski,Michael Wang +12 more
TL;DR: Single‐agent carfilzomib was generally well tolerated for up to 12 treatment cycles and showed activity in patients with relapsed and/or refractory multiple myeloma who had received prior treatment with bortezomib.
Journal ArticleDOI
Carfilzomib in multiple myeloma patients with renal impairment: pharmacokinetics and safety
Ashraf Badros,Ravi Vij,Thomas Martin,Jeffrey A. Zonder,Lori Kunkel,Zhengping Wang,Susan Lee,Alvin F. Wong,Ruben Niesvizky +8 more
TL;DR: The pharmacokinetics and safety of carfilzomib were not influenced by the degree of baseline renal impairment, including in patients on dialysis, and carfilZomib was well tolerated and demonstrated promising efficacy.
Journal ArticleDOI
An open-label single-arm pilot phase II study (PX-171-003-A0) of low-dose, single-agent carfilzomib in patients with relapsed and refractory multiple myeloma.
Sundar Jagannath,Ravi Vij,A. Keith Stewart,Suzanne Trudel,Andrzej Jakubowiak,Tony Reiman,George Somlo,Nizar J. Bahlis,Sagar Lonial,Lori Kunkel,Alvin F. Wong,Robert Z. Orlowski,David S. Siegel +12 more
TL;DR: The PX-171-003-A0 pilot study as mentioned in this paper was the first single-agent trial conducted with carfilzomib and achieved the best ORR of 16.7% with a median duration of response of 13.8 months.